Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

Type
Public
HQ
Irving, US
Founded
2002
Size (employees)
75 (est)
Reata Pharmaceuticals was founded in 2002 and is headquartered in Irving, US
Report incorrect company information

Key People/Management at Reata Pharmaceuticals

Warren Huff

Warren Huff

President and CEO

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has an office in Irving
Irving, US (HQ)
150 2801 Gateway Dr
Show all (1)
Report incorrect company information

Reata Pharmaceuticals Financials and Metrics

Reata Pharmaceuticals Financials

Reata Pharmaceuticals's revenue was reported to be $49.86 m in FY, 2016 which is a 0.9% decrease from the previous period.
USD

Net income (Q1, 2018)

4.1 m

Closing share price (11-May-2018)

31.8

Cash (31-Mar-2018)

105.9 m
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

50.3 m49.9 m

Revenue growth, %

(1%)

General and administrative expense

13.7 m16.6 m23.3 m

R&D expense

35.1 m39.5 m71.3 m
Quarterly
USDQ1, 2018

General and administrative expense

6.6 m

R&D expense

21.4 m

Operating expense total

28.1 m

Depreciation and amortization

101 k
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

42 m84.7 m129.8 m

Inventories

2.6 m

Current Assets

77.3 m87.3 m133.1 m

PP&E

1.1 m819 k718 k
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

92.4 m95.7 m82.7 m65.2 m105.9 m

Current Assets

112.9 m99.9 m85.7 m68.9 m134.7 m

PP&E

942 k899 k703 k671 k829 k

Total Assets

114.4 m101.8 m88.2 m71.3 m136.8 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(1.5 m)(6.2 m)(47.7 m)

Depreciation and Amortization

1.8 m682 k437 k

Inventories

(1.2 m)

Accounts Payable

299 k(1.8 m)
Quarterly
USDQ1, 2018

Net Income

4.1 m

Depreciation and Amortization

101 k

Accounts Payable

(1.1 m)

Cash From Operating Activities

(24 m)
USDY, 2018

Financial Leverage

-1 x
Show all financial metrics

Reata Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

240

Patents Pending

280

Phase II Trials Products

4

Phase III Trials Products

1
Show all operating metrics
Report incorrect company information